Announcement of Extraordinary General Meeting
Oslo: Ultimovacs ASA is set to hold an extraordinary general meeting (EGM) to discuss pivotal company developments. This follows a recent notice concerning a business combination with Zelluna Immunotherapy AS. The announcement includes crucial documents related to the EGM, ensuring transparency for all stakeholders.
Date and Format of the Meeting
The EGM is scheduled for January 9, 2025, at 09:00 CET. In light of current circumstances, this meeting will be conducted electronically, allowing shareholders to participate from the comfort of their homes or offices.
How to Participate
To attend the EGM, shareholders will need to access the meeting platform using provided login credentials. It’s essential for participants to ensure that they have the necessary information ready for a seamless experience.
Board Proposals and Attachments
The Board of Directors urges all shareholders to review the attached documents, which outline the key matters to be voted on during the meeting. Each document can provide insights into the business strategy and forthcoming actions of Ultimovacs ASA.
Essential Documents Available
All relevant materials related to the EGM, including the notice and appendices, are accessible on the company’s official website. It is recommended that participants familiarize themselves with these materials ahead of the meeting to make informed decisions.
Contact Information for Further Inquiries
For any questions regarding the EGM or the documents provided, shareholders are encouraged to reach out. Hans Vassgård Eid, the Interim CEO and CFO, is available for further clarification through the provided email or phone number.
Understanding the Business Combination
This meeting also represents a pivotal moment for Ultimovacs ASA as it explores its collaboration with Zelluna Immunotherapy AS. With the growing interest in immunotherapy, this combination could open new avenues for innovation and development in the medical field.
Frequently Asked Questions
1. What is the purpose of the extraordinary general meeting?
The EGM aims to discuss key proposals from the Board, including the business combination with Zelluna Immunotherapy AS.
2. How can I participate in the EGM?
Shareholders can log in to the designated platform with the provided user ID and password to attend the meeting electronically.
3. Where can I find the documents related to the EGM?
All documents are available on the Ultimovacs ASA website under the investor relations section.
4. Who can I contact for more information?
For questions, you can contact Hans Vassgård Eid, Interim CEO, via email or phone for assistance.
5. Why is the business combination significant for Ultimovacs?
The merger with Zelluna Immunotherapy AS is expected to enhance Ultimovacs' capabilities in the rapidly evolving field of immunotherapy.